Clinical Application of Stem Cells in the Cardiovascular System

Author(s):  
Christof Stamm ◽  
Kristin Klose ◽  
Yeong-Hoon Choi
2020 ◽  
Vol 15 (3) ◽  
pp. 187-201 ◽  
Author(s):  
Sunil K. Dubey ◽  
Amit Alexander ◽  
Munnangi Sivaram ◽  
Mukta Agrawal ◽  
Gautam Singhvi ◽  
...  

Damaged or disabled tissue is life-threatening due to the lack of proper treatment. Many conventional transplantation methods like autograft, iso-graft and allograft are in existence for ages, but they are not sufficient to treat all types of tissue or organ damages. Stem cells, with their unique capabilities like self-renewal and differentiate into various cell types, can be a potential strategy for tissue regeneration. However, the challenges like reproducibility, uncontrolled propagation and differentiation, isolation of specific kinds of cell and tumorigenic nature made these stem cells away from clinical application. Today, various types of stem cells like embryonic, fetal or gestational tissue, mesenchymal and induced-pluripotent stem cells are under investigation for their clinical application. Tissue engineering helps in configuring the stem cells to develop into a desired viable tissue, to use them clinically as a substitute for the conventional method. The use of stem cell-derived Extracellular Vesicles (EVs) is being studied to replace the stem cells, which decreases the immunological complications associated with the direct administration of stem cells. Tissue engineering also investigates various biomaterials to use clinically, either to replace the bones or as a scaffold to support the growth of stemcells/ tissue. Depending upon the need, there are various biomaterials like bio-ceramics, natural and synthetic biodegradable polymers to support replacement or regeneration of tissue. Like the other fields of science, tissue engineering is also incorporating the nanotechnology to develop nano-scaffolds to provide and support the growth of stem cells with an environment mimicking the Extracellular matrix (ECM) of the desired tissue. Tissue engineering is also used in the modulation of the immune system by using patient-specific Mesenchymal Stem Cells (MSCs) and by modifying the physical features of scaffolds that may provoke the immune system. This review describes the use of various stem cells, biomaterials and the impact of nanotechnology in regenerative medicine.


2016 ◽  
Vol 118 (1) ◽  
pp. 127-137 ◽  
Author(s):  
Sadie C. Slater ◽  
Michele Carrabba ◽  
Paolo Madeddu

Cancers ◽  
2018 ◽  
Vol 10 (11) ◽  
pp. 446 ◽  
Author(s):  
Jui-Hua Lu ◽  
Bou-Yue Peng ◽  
Chun-Chao Chang ◽  
Navneet Dubey ◽  
Wen-Cheng Lo ◽  
...  

Cancer is a leading cause of mortality and a major public health problem worldwide. For biological therapy against cancer, we previously developed a unique immunotherapeutic platform by combining mesenchymal stem cells with an antigen-specific protein vaccine. However, this system possesses a few limitations, such as improperly immortalized mesenchymal stem cells (MSCs) along with transfected oncogenic antigens in them. To overcome the limitations of this platform for future clinical application, we freshly prepared primary adipose-derived stem cells (ADSCs) and modified the E7’ antigen (E7’) as a non-oncogenic protein. Either subcutaneously co-inoculated with cancer cells or systemically administered after tumor growth, ADSC labeled with enhanced green fluorescent protein (eGFP) and combined with modified E7’ (ADSC-E7’-eGFP) cells showed significant antitumor activity when combined with the protein vaccine in both colon and lung cancer in mice. Specifically, this combined therapy inhibited tumor through inducing cell apoptosis. The significantly reduced endothelial cell markers, CD31 and vascular endothelial growth factor (VEGF), indicated strongly inhibited tumor angiogenesis. The activated immune system was demonstrated through the response of CD4+ T and natural killer (NK) cells, and a notable antitumor activity might be contributed by CD8+ T cells. Conclusively, these evidences imply that this promising immunotherapeutic platform might be a potential candidate for the future clinical application against cancer.


2019 ◽  
Vol 14 ◽  
pp. 134-147 ◽  
Author(s):  
Juliane W. Schott ◽  
Diego León-Rico ◽  
Carolina B. Ferreira ◽  
Karen F. Buckland ◽  
Giorgia Santilli ◽  
...  

2016 ◽  
Vol 45 (4) ◽  
pp. 765-774 ◽  
Author(s):  
Shiva Gholizadeh-Ghaleh Aziz ◽  
Ezzatollah Fathi ◽  
Mohammad Rahmati-Yamchi ◽  
Abolfazl Akbarzadeh ◽  
Zahra Fardyazar ◽  
...  

2013 ◽  
Vol 14 (3) ◽  
pp. 367 ◽  
Author(s):  
Jun-Gu Kang ◽  
Sang-Bum Park ◽  
Min-Soo Seo ◽  
Hyung-Sik Kim ◽  
Joon-Seok Chae ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document